



4686972000	sobi.com										Solna, SWEDEN Inc 2001										MGMT owns --										
EPS Rank 36																															
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haematology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden. <a href="#">LESS</a>																															
<b>ANNUAL - DEC END</b>																<b>2024 Estimate</b>								<b>2025 Estimate</b>							
EPS SEK	0.23	2.86	4.08	8.57	10.78	10.52	8.67	8.52	7.47	9.63	29%	14.61	52%																		
CASH FLOW/SHR SEK	1.81	1.22	4.72	7.38	11.79	16.73	17.60	14.93	13.71	<b>Earnings Growth Rate</b>								<b>Sales Growth Rate</b>													
PRETAX MARGIN %	3%	20%	24%	34%	30%	28%	21%	18%	13%	2022-24 -8% (13 Stability)								2022-24 18%													
RETURN ON EQUITY %	1%	16%	19%	31%	25%	18%	12%	11%	8%	2020-24 -6% (13 Stability)								13%													
SALES % CHANGE	24%	61%	25%	40%	56%	7%	2%	21%	18%	<b>COMP RATING</b> 75								<b>SMR RATING</b> A													
SALES (MIL) SEK	3,228	5,204	6,511	9,139	14K	15K	16K	19K	22K	<b>INV T/O</b> 2.2x 46																					
<b>WEEKLY</b>																<b>DEBT %</b> 2021-23 39%								<b>2021-23</b> 12%							
DATAGRAPH RATING	54	60	59	63	55	62	60	60	59	<b>TAX RATE</b> 2021-23 19%								<b>2021-23</b> 21%													
AVG DAILY VOL (000)	329	334	335	349	345	351	402	386	389	<b>BACKLOG</b> 2021-23 --																					
UP/DOWN VOLUME	1.7	1.7	1.9	2.0	1.8	2.0	1.5	1.6	1.3	<b>R &amp; D</b> 12.30%								<b>BK VAL</b> 3.05x '23													
ACCUM/DIST RATING	2	33	24	33	34	38	19	21	6	<b>DIV SEK</b> None								<b>DIV GR RT--</b>													
RELATIVE STRENGTH	65	81	74	77	78	82	79	80	71	<b>BETA</b> 0.59(7.00)								<b>ALPHA</b> 0.09 (0.05)													
GROUP RANK	54	31	35	31	37	28	21	21	24	<b>2023 EMPLOYEES</b> 1,772 (14%)																					



<b>FINANCIALS</b>	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	P/E	48
EPS (SEK)	0.90	4.87	2.26	0.87	1.53	4.02	1.76	0.83	1.46	4.47	3.44	0.71	0.30	3.02	2.35	0.66	2.26e	4.07e	3.63e	2.94e	2024 Est.:	31.5
EPS % CHANGE	-49%	+10%	-41%	-5%	+70%	-17%	-22%	-5%	-5%	+11%	+95%	-14%	-79%	-32%	-32%	-7%	+653%e	+35%e	+54%e	+345%e	2025 Est.:	20.8
SALES (MIL SEK)	2,970.0	4,581.0	3,661.0	3,211.0	3,761.0	4,896.0	4,925.0	3,876.0	3,999.0	5,991.0	5,239.0	4,872.0	5,168.0	6,844.0	6,256.0	5,442.0	6,038.1e	7,244.3e	6,438.0e	6,087.0e	5-yr High:	47
SALES % CHANGE	+1%	-6%	-21%	+5%	+27%	+7%	+35%	+21%	+6%	+22%	+6%	+26%	+29%	+14%	+19%	+12%	+17%e	+6%e	+3%e	+12%e	5-yr Low:	11
EPS % SURPRISE	-10.6%	+15.4%	-9.5%	+39.1%	+4.3%	+23.5%	+27.8%	+15.3%	+10.1%	+6.0%	+5.9%	+39.0%	+46.7%	-15.7%	+0.3%	-13.6%					vs Ind. Avg:	
FUNDS	392	375	365	340	311	266	297	587	700	781	803	833	831	876	944	923	910					
SHARES HELD BY FUNDS	88M	68M	66M	58M	48M	38M	47M	61M	66M	66M	67M	66M	75M	88M	95M	94M	96M					